Kornimate/medical-research-clean huggingface dataset:
drug abuse prevention among girls through a mother-daughter intervention

Conditions: Substance Use

Summary: the purpose of this study is to determine a computer- and family-based drug abuse prevention program is able to reduce drug use among early adolescent girls.

this study longitudinally tested a computerized, parent-involvement substance abuse prevention program for adolescent girls and their mothers. the prevention program aimed to strengthen and sustain the mother-daughter bond while equipping girls with the necessary information and skills to increase protective factors and reduce risk factors associated with tobacco, alcohol, and other harmful substance use.

Eligibility criteria:
inclusion criteria: * english-speaking new york city (nyc) area girls * ages 11 - 13 years * must have private access to a computer with high-speed connectivity exclusion criteria: * non-english-speaking girls who do not live in the nyc area * younger than 11 or older than 13 years of age * those who lack of private access to a computer with high-speed connectivity

Keywords: drugs youth parent computer prevention
low-cost contingency management for hispanic outpatients - 3

Conditions: Substance Abuse

Summary: the purpose of this study is to evaluate the effectiveness of a lower-cost contingency management (cm) procedure in hispanic substance abusing outpatients. thirty individuals meeting dsm-iv criteria for substance dependence receive one of two conditions: (a) standard treatment, or (b) standard treatment plus prize cm. using a cross-over design, cm is implemented in a community-based outpatient clinic and compared with non-cm in the same clinic. the participating clinic is randomly assigned to receive either the cm or non-cm phase first; 15 weeks after the final participant in one phase is enrolled, a one-week washout period occurs, followed by a switch to the other phase. patients initiating outpatient treatment during the non-cm phase receive standard treatment and submit urine and breath samples 2/week during weeks 1-6 and 1/week during weeks 7-12. patients initiating treatment during the cm phase also receive standard treatment and the same breath and urine monitoring. in addition, they earn the opportunity to win prizes for coming to treatment and for submitting negative breath and urine samples. follow-up interviews are conducted at 1,3,6 and 9 months following intake during which substance use and psychosocial functioning are assessed.


Eligibility criteria:
inclusion criteria: * age \> 18 years * current dsm-iv substance dependence. exclusion criteria: * have a serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk) on the basis of history or medical examination * have dementia (\<23 on the mini mental state exam; folstein et al. 1975) * dsm-iv diagnosis of pathological gambling * plans to move from the hartford are within 9 months.

Keywords: contingency management substance abuse
syngo native contrast enhanced 3d mra on 3t verio magnet

Conditions: Vascular Disease

Summary: the purpose of the study is to compare non-contrast abdominal mr angiogram (mra) syngo native sequence performed on a 3t verio siemens magnet to a standard contrast-enhanced mra performed as part of routine clinical care in patients with normal renal function to determine if the non-contrast native sequence is a viable alternative to contrast enhanced mra in patients with renal insufficiency. there are no interventions--this is an observational study.

if the native sequence proves to be a viable alternative to contrast enhanced mra it will provide imaging physicians with the diagnostic tool to assess vascular disease in patients with renal insufficiency without placing them at risk for additional co-morbidities.

Eligibility criteria:
inclusion criteria: over age 18 signed informed consent referred for standard of care mra exclusion criteria: no contra-indications for mri/mra ie implants which could interfere with magnets renal insufficiency which would preclude use of contrast-enhanced contrast for a standard of care mra

Keywords: mra syngo native gadolinium non contrast
human pharmacology study (keppra dry syrup bioequivalence study)

Conditions: Healthy

Summary: to demonstrate the bioequivalence of a levetiracetam dry syrup (50% (500mg/1000mg)) versus levetiracetam 500 mg oral tablet, used as reference, after single dose administration in healthy japanese subjects.


Eligibility criteria:
inclusion criteria: * written informed consent dated and signed by subject. * healthy male or female japanese volunteer from the first generation, living outside of japan for less than 10 years, age range 20 to 55 years inclusive. * body mass index (bmi) between 18.0 and 28.0 kg/m² inclusive. exclusion criteria: * pregnant, lactating or sexually active women with childbearing potential who are not using a medically accepted birth control method. * history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, neurological, psychiatric disorders capable of altering the absorption, metabolism or elimination of drugs, or of constituting a risk factor when taking the study medication. * history of drug addiction or presence of drug addiction (positive drug screen) or excessive use of alcohol (weekly intake in excess of 21 units alcohol for male and 14 units alcohol for female; one unit alcohol equals one glass of beer or lager, a glass of wine or a measure of spirits), of psychological or other emotional problems that are likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements. * heavy caffeine drinker (drinking \>5 cups of coffee or equivalent, approximately 500mg of caffeine per day). * smokers of more than 10 cigarettes per day or smokers not willing to abstain from smoking while in the clinic for each period.

Keywords: levetiracetam healthy volunteers healthy subjects
effectiveness of ipack on postoperative pain from hamstring autograft following acl repair

Conditions: Pain, Postoperative; ACL Injury; Anesthesia, Local; Opioid Use

Summary: patients undergoing acl repair with hamstring autograft frequently develop significant post operative pain at the hamstring grafting site. this pain is within the distribution of a commonly used regional nerve block, the interspace between the popliteal artery and capsule of the knee (ipack). the investigators plan to randomize consenting patients to either receiving a sham injection of normal saline or to an interventional group of long acting local anesthetic (ropivacaine) injected in the popliteal fossa between the popliteal artery and capsule of the knee (ipack). both groups of patients will receive standard of care with respect to perioperative pain management, which includes a preoperative adductor canal nerve block and preoperative acetaminophen administration. dual primary endpoints of postoperative pain scores and mean postoperative opioid use will be retrieved and compared between groups. additional secondary endpoints will be pacu length of stay, pacu opioid use, pod1 opioids use, and pod1 pain scores (best, worst, average).


Eligibility criteria:
inclusion criteria: * undergoing acl surgery with expected hamstring autograft by dr. catherine robertson at uc san diego * at least 18 years of age * able to provide consent in english prior to surgery exclusion criteria: * pregnancy (a urine pregnancy test is standard at ucsd for female patients prior to menopause who are sexually active with the opposite sex within the previous year) * inability to communicate with the investigators and hospital staff * severe renal, hepatic or cardiac disease * chronic high-dose opioid use (defined as daily use for more than 4 weeks prior to surgery of at least the equivalent of 20 mg oxycodone) * bmi \> 45 kg/m2 * allergy to study medications (lidocaine, bupivacaine) * incarceration.
effects of internet-based storytelling programs in reducing mental illness stigma with mediation by interactivity and stigma content

Conditions: COMBO Condition; STIGMA Condition; INTERACT Condition; CONTROL Condition

Summary: mental illness stigma has been a concerning issue globally due to its adverse effects on the recovery of people with mental illness and may delay help-seeking for mental health out of the concern of being stigmatized. with technological advancement, internet-based mental health stigma reduction interventions have been developed to combat mental illness stigma and the effects have been promising. the present study aimed to examine the differential effects of internet-based storytelling programs varied on level of interactivity and stigma content in reducing mental illness stigma. in the present study, the investigator hypothesized that an internet-based storytelling program with a combination of interactivity and stigma content would lead to the most significant reduction in public stigma, microaggression, and social distance from people with mental illnesses, followed by internet-based storytelling program with stigma content-only and interactivity-only, compared with control. secondly, the investigator hypothesized that the effects observed in stigma reduction would be mediated by perceived autonomy and immersiveness due to the presence of interactivity.


Eligibility criteria:
inclusion criteria: * aged 18 years or above * able to read and understand chinese exclusion criteria: * less than 18 years of age * unable to read or understand chinese

Keywords: mental illness stigma internet-based interactivity storytelling social distance microaggression
nutrigenomics of zinc supplementation in insulin secretion and diabetes

Conditions: Diabetes

Summary: the purpose of this study is to evaluate the effect of zinc supplementation on insulin secretion by genotype of slc30a8.

as diabetes increases at an alarming rate, strategies for prevention of this disease must be developed. for a given individual, there are both biologic (e.g., genetic) and environmental (e.g., lifestyle) factors that comprise her individual risk of diabetes. researchers can take advantage the accumulating knowledge of these individual factors to design individualized strategies for diabetes risk assessment and prevention. for example, a mutation in a particular gene, slc30a8, which encodes a zinc transporter, has been shown to increase the risk of diabetes probably through impairment of insulin secretion. in the proposed research project, the investigators aim to conduct a pilot study to see the effect of zinc supplementation on insulin secretion in people with and without this genetic mutation to see if zinc can improve insulin secretion in those with the mutation. the results from this study will help the investigators to plan a larger, more definitive study to determine if zinc supplementation can be used to prevent or treat diabetes in those with this mutation in slc30a8.

Eligibility criteria:
inclusion criteria: * aged 21-70 years * amish decent * genotyping of rs13266634 of slc30a8 gene * previously consented to contact for future studies and future use of dna exclusion criteria: * subject is a first-degree relative of another subject with the same slc30a8 genotype * diabetes mellitus (by history, treatment or random bg\>200 mg;dl) * gastrointestinal disease causing nausea, vomiting, or diarrhea including inflammatory bowel disease by history. * rheumatoid arthritis by history * albumin \< 3.5 g/dl * hemochromatosis by history * hematocrit \<34% * liver disease by history * alanine aminotransferase or aspartate aminotransferase greater than 2.5 times normal * renal failure by history * estimated glomerular filtration rate \< 60 ml/min by mdrd equation * use of thiazide diuretic and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation * use of systemic corticosteroid and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation * use of highly-active antiretroviral medications * use of antipsychotic medications * use of quinolone antibiotics * use of tetracycline antibiotic and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation * use of chelation therapy in the past month * unwilling to withdraw from supplements for 1 week prior to the study and throughout study * abnormal thyroid stimulating hormone (tsh) level * serious disease precluding participation * reported pregnancy or positive urine hcg test * cancer diagnosis in past 2 years * breastfeeding * use of denture adhesive

Keywords: zinc diabetes genetics
to investigate the effect of tart montmorency cherry juice (prunus cerasus) on vascular function.

Conditions: Hypertension

Summary: given the global health issues associated with poor cardiovascular function, interventions that help reduce the severity, with emphasis on prevention would not only have economic implications, but would also improve health, wellbeing and quality of life. research provides evidence that consumption of a diet high in plant foods and rich is polyphenols is associated with a reduction in the incidence of cardiovascular disease (hung et al 2004). tart montmorency cherries have been shown to be high in numerous phytochemicals (wang et al 1999; seeram et al 2001). several of these compounds, are known to be vasoactive and improve blood vessel function by increasing bioavailability of vasodilators (mudnic et al 2012), reducing vasoconstrictors (broncel et al 2010), decreasing platelet aggregation (hubbart et al 2006) and increasing blood vessel dilation (schroeter et al 2006). impaired function of the lining of blood vessels (endothelial dysfunction) has been linked to increased risk of cardiovascular disease. however, the bioavailability of all the compounds in tart montmorency cherry juice and their efficacy with respect to vascular function has not been fully determined. this study will examine the influence of tart montmorency cherry juice on cardiovascular function, specifically arterial stiffness by pulse wave velocity and blood flow in the microcirculation by laser doppler imaging. this study will also examine digital volume pulse and pulse wave analysis. these data will provide information on the ability of tmcj to affect blood flow and vascular function.

participants provided blood samples immediately before supplementation and sequentially 8h post ingestion. additionally, vascular measurements including laser doppler imaging (ldi), pulse wave analysis (pwa), pulse wave velocity (pwv), digital volume pulse (dvp) and blood pressure (bp) were performed with the participant in a supine position. ldi, pwv, pwa, and dvp were measured at 1, 2, 3, 5 and 8h intervals. bp was performed at hourly intervals. all vascular measurements took place on the non - cannulated arm. no additional food or fluid was provided during the study period except for low-nitrate mineral water. following a minimum of two weeks washout, the participants were required to return to the laboratory to repeat the procedure with the other intervention drink.

Eligibility criteria:
inclusion criteria: * those with blood pressure below 140/90 * males * aged 21 - 55y exclusion criteria: * those with blood pressure above 140/90 * taken other medication/ supplements. * those aged \>21 or \<55.

Keywords: vascular function tart montmorency cherries arterial stiffness blood flow
acute respiratory distress syndrome in taiwan

Conditions: Acute Respiratory Distress Syndrome

Summary: the study enrolls ards patients in medical icus in 11 hospitals in taiwan. the epidemiology and long-term outcomes of the patients will be recorded.


Eligibility criteria:
inclusion criteria: * age \>18 years * patients in medical intensive care unit in sep., 2017 and jan., 2018. exclusion criteria: * age less than 18 years. * pregnancy.
point-of-care follow-up with primary care after emergency department discharge

Conditions: Conditions Influencing Health Status

Summary: the purpose of this trial is to determine whether setting up a follow-up appointment for patients who received treatment and were discharged from the emergency department increases their compliance with the follow-up appointment. we are enrolling patients who need a follow-up visit, have health insurance but report do not have a primary care doctor. patients are randomized to one of three treatment groups: (1) assistance setting up a follow-up appointment by a research assistant using zocdoc; (2) zocdoc information given to the subject to set up follow-up appointment by him/herself; or (3) usual discharge instructions by ed staff. subjects are phoned approximately 2 weeks after the ed visit and asked whether they completed a follow-up visit, satisfaction with their ed visit, satisfaction with their follow-up visit, and additional ed treatment and recovery.

this is a randomized controlled trial involving adult emergency department (ed) patients who need a follow-up visit as defined by the ed provider (importance of follow-up rated as 5 or greater on a 0 to 10 scale). there is software available called zocdoc that provides a user the ability to identify primary care providers who have open appointments and will take the person's health insurance (in network and outside of network) and list the doctors based on their proximity to the person in need. we are testing whether booking appointments for ed patients using zocdoc vs. giving patients the information to use zocdoc themselves vs. standard discharge instructions given by ed staff (i.e. you should follow-up with a primary care doctor) affects compliance with self-reported follow-up visits. we are enrolling patients while they are in the ed, completed a short baseline interview and then another interview with them over the telephone approximately two weeks after the index ed visit. the follow-up interview asks subjects whether they have completed a follow-up visit, satisfaction with the ed visit and the primary care visit, any other additional ed treatment and extent of recovery from the problem that brought them to the ed the first time.

Eligibility criteria:
inclusion criteria: patients with health insurance but report not having a primary care provider and are rated by the ed provider as needing a follow-up visit with a primary care provider (rated as moderate to high need by ed provider). - exclusion criteria: patients doesn't want a primary care provider or patient doesn't want a follow-up visit. patient is unable to understand consent, is a prisoner, or does not have access to email (because zocdoc sends appointment information to email). -
gemcitabine with or without tipifarnib (r115777) in treating patients with advanced pancreatic cancer

Conditions: Pancreatic Neoplasms

Summary: the purpose of this study is to compare the effectiveness of gemcitabine with or without tipifarnib (r115777) in patients who have advanced pancreatic cancer.

this is a randomized (study drug assigned by chance), double-blind (neither the investigator or patient will know the identity of the assigned treatment) to compare the overall survival of patients with advanced pancreatic cancer after treatment with gemcitabine with and without tipifarnib (referred to as r115777). gemcitabine is an approved chemotherapy agent administered intravenously (iv) (though a vein) for patients with advanced pancreatic cancer. r115777 is an orally (by mouth) administered investigational drug that is being tested in combination with gemcitabine for the treatment of patients with advanced pancreatic cancer. patients will continue to receive treatment with gemcitabine and r115777 (or placebo) unless disease progression or unacceptable toxicity is observed. all patients in the study will be followed for study assessments and safety for up to the 5 years, the start of further treatment, or death (whichever comes first). r115777 (or matching placebo) 200 mg will be orally administered at intervals of approximately 12 hours daily throughout the study. gemcitabine will be administered iv at a starting dose of 1000 mg/m2 every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter. treatment with gemcitabine and tipifarnib (or placebo) will continue for up to 5 years (or until the start of further treatment) in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria: * pathological (confirmed by biopsy) diagnosis of pancreatic cancer * have an eastern cooperative oncology group (ecog) performance score of 0 to 1 (defined as a patient who does not have symptoms of pancreatic cancer and is fully active or who has symptoms but is able to light work) exclusion criteria: * have absolute neutrophil (white blood cell) count, platelet count (blood clotting factors), or results from liver function tests considered by the investigator to be significantly abnormal * newly diagnosed disease that has the potential for curative surgical resection * prior therapy with any chemotherapy, or any other systemic therapy for pancreatic cancer * have cardiovascular disease considered by the investigator to be uncontrolled or severe

Keywords: stage ii pancreatic cancer stage iii pancreatic cancer recurrent pancreatic cancer adenocarcinoma of the pancreas stage iv pancreatic cancer
a nutritional management algorithm in older patients with locally advanced esophageal cancer

Conditions: Localized Stage I-III Esophageal Cancer; Gastroesophageal Junction Cancer

Summary: patients with esophageal and gastroesophageal junction (gej) cancer often have weight loss, swallowing problems, and poor appetite. this may affect their ability to tolerate cancer treatment. the purpose of this study is to see if the researchers can apply a set of nutrition guidelines designed specifically for patients with cancer who are older than 65 years of age. the questions will allow them to assess the nutritional status and make appropriate referrals. if the patients are having swallowing problems or losing weight, the researchers want to address the nutritional problems early in the course of their treatment.


Eligibility criteria:
inclusion criteria: * patients must be ≥ age of 65; no maximum age limit. * patients who will receive induction chemotherapy followed by combined chemoradiotherapy at mskcc for localized stage i-iii esophageal or gastroesophageal junction cancer. * patients can receive chemoradiotherapy preoperatively prior to surgical resection or as definitive/primary chemoradiotherapy. * patients can be kps ≥60, as long as primary provider feels that patient is candidate for combined modality chemoradiotherapy * be able to provide informed consent exclusion criteria: * enrolled on a phase i trial * patients with a feeding tube previously placed. * not english-speaking

Keywords: nutritional management algorithm nutritional and functional assessments 13-264
prediction of the effectiveness of hypofractionated radiation therapy in early stage lung cancer by bio-imaging and biomarkers

Conditions: Inoperable Early Stage Non-small Cell Lung Cancer

Summary: surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (i-ii) non-small cell lung cancer (nsclc). selected patients unwilling or unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy. this has shown to result in a long term local disease control rate and a high cancer specific survival. the current trial addresses the issue if progression free survival (pfs) in patients treated with radiotherapy can be predicted by a multi-variate model derived from a composite of bio-imaging and biomarkers


Eligibility criteria:
inclusion criteria: * proof of ct1a/b - 2a/b n0m0 nsclc * informed consent signed * resectable tumour * \> 18 years old * men and women

Keywords: inoperable early stage non-small cell lung cancer radiation therapy